Drug Discovery
-
Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia
Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia April 26, 2021 Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C...
26 Apr 2021
-
20 Apr 2021
Janux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials
Janux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials April 20, 2021 Janux Therapeutics today announced the closing of a $125 million Series B financing led by RA Capi...
-
16 Mar 2021
StrideBio Announces Closing of $81.5M Series B Financing
StrideBio Announces Closing of $81.5M Series B Financing March 16, 2021 StrideBio, Inc., a leading developer of novel engineered adeno-associated virus (AAV) based gene therapies, today announced the closing of an oversubscribed Seri...
-
12 Mar 2021
Sanofi and Translate Bio Initiate Phase 1/2 Clinical Trial of mRNA COVID-19 Vaccine Candidate
Sanofi and Translate Bio Initiate Phase 1/2 Clinical Trial of mRNA COVID-19 Vaccine Candidate March 12, 2021 Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeu...
-
4 Mar 2021
Amgen to Acquire Five Prime Therapeutics for $1.9 Billion in Cash
Amgen to Acquire Five Prime Therapeutics for $1.9 Billion in Cash March 4, 2021 Amgen (NASDAQ: AMGN) and Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncol...
-
4 Mar 2021
Exscientia Completes $100 Million Series C Financing Round with BlackRock Funds
Exscientia completes $100 million Series C financing round with BlackRock funds March 4, 2021 Proceeds to further accelerate AI drug discovery platform and pipeline Exscientia, a clinical stage pharmatech pioneering the use of artificial intelligence ...
-
2 Mar 2021
WuXi AppTec Completes Acquisition of OXGENE to Further Strengthen Cell and Gene Therapy Service Offerings for Global Customers
WuXi AppTec Completes Acquisition of OXGENE to Further Strengthen Cell and Gene Therapy Service Offerings for Global Customers March 2, 2021 WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services i...
-
19 Jan 2021
Immuneering Raises $62m in Series B Round
Immuneering raises $62m in Series B round January 19, 2021 Immuneering has raised $62m in an oversubscribed Series B round led by high-profile life science investors. The money will be used to support the company's portfolio – particularly its le...
-
14 Jan 2021
NewAmsterdam Pharma Completes $196M (€160M) Series A Funding for Comprehensive Phase 3 Development Program
NewAmsterdam Pharma Completes $196M (€160M) Series A Funding for Comprehensive Phase 3 Development Program January 14, 2021 Founding investor Forbion joined by co-lead investors, Morningside Ventures and Ascendant BioCapital, and other leaders in...
-
11 Jan 2021
Sanofi to Acquire Kymab, Adding KY1005 to Its Pipeline, a Human Monoclonal Antibody Targeting Key Immune System Regulator OX40L
Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L January 11, 2021 Sanofi and Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibod...
Join Our Newsletter for Free
